|
DE10347710B4
(de)
|
2003-10-14 |
2006-03-30 |
Johannes-Gutenberg-Universität Mainz |
Rekombinante Impfstoffe und deren Verwendung
|
|
DE102005046490A1
(de)
|
2005-09-28 |
2007-03-29 |
Johannes-Gutenberg-Universität Mainz |
Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
|
|
US9732131B2
(en)
|
2006-02-27 |
2017-08-15 |
Calviri, Inc. |
Identification and use of novopeptides for the treatment of cancer
|
|
CN102625832A
(zh)
|
2009-08-24 |
2012-08-01 |
贝勒医学院 |
产生对多种肿瘤抗原或多种病毒特异的ctl细胞系
|
|
EP2569633B1
(en)
*
|
2010-05-14 |
2016-02-10 |
The General Hospital Corporation |
Compositions and methods of identifying tumor specific neoantigens
|
|
PL3892295T3
(pl)
*
|
2011-05-24 |
2023-07-24 |
BioNTech SE |
Zindywidualizowane szczepionki przeciwnowotworowe
|
|
EP3892295B1
(en)
*
|
2011-05-24 |
2023-04-26 |
BioNTech SE |
Individualized vaccines for cancer
|
|
US20140303020A1
(en)
*
|
2011-08-02 |
2014-10-09 |
The University Of Tokyo |
Method for Assessing Myelodysplastic Syndrome or Myeloid Tumor Predisposition, Polypeptide and Antibody Therefor, and Candidate Screening Method for Therapeutic Drug or Prophylactic Drug Therefor
|
|
ES2602072T3
(es)
*
|
2011-09-29 |
2017-02-17 |
Trovagene, Inc. |
Mutaciones en SF3B1 y leucemia linfocítica crónica
|
|
WO2013086464A1
(en)
*
|
2011-12-07 |
2013-06-13 |
The Broad Institute, Inc. |
Markers associated with chronic lymphocytic leukemia prognosis and progression
|
|
GB201121308D0
(en)
|
2011-12-12 |
2012-01-25 |
Cell Medica Ltd |
Process
|
|
ES2748652T3
(es)
|
2012-02-09 |
2020-03-17 |
Baylor College Medicine |
Mezclas pep para generar CTL multivíricos con amplia especificidad
|
|
WO2013143555A1
(en)
|
2012-03-26 |
2013-10-03 |
Biontech Ag |
Rna formulation for immunotherapy
|
|
CA2886218A1
(en)
|
2012-05-25 |
2013-11-28 |
Phosimmune, Inc. |
Identification of mhc class i phospho-peptide antigens from breast cancer utilizing shla technology and complementary enrichment strategies
|
|
WO2014012051A1
(en)
*
|
2012-07-12 |
2014-01-16 |
Persimmune, Inc. |
Personalized cancer vaccines and adoptive immune cell therapies
|
|
GB201214007D0
(en)
*
|
2012-08-07 |
2012-09-19 |
Scancell Ltd |
Anti-tumour immune responses to modified self-epitopes
|
|
US9561266B2
(en)
|
2012-08-31 |
2017-02-07 |
University Of Virginia Patent Foundation |
Target peptides for immunotherapy and diagnostics
|
|
WO2014039675A2
(en)
|
2012-09-05 |
2014-03-13 |
University Of Virginia Patent Foundation |
Target peptides for colorectal cancer therapy and diagnostics
|
|
LT2901341T
(lt)
|
2012-09-28 |
2019-09-25 |
The University Of Connecticut |
Protekcinių vėžio epitopų identifikavimas, skirtas vėžio gydymui
|
|
EP3417874B1
(en)
|
2012-11-28 |
2024-09-11 |
BioNTech SE |
Individualized vaccines for cancer
|
|
GB2508414A
(en)
*
|
2012-11-30 |
2014-06-04 |
Max Delbrueck Centrum |
Tumour specific T cell receptors (TCRs)
|
|
EP3292873B1
(en)
|
2013-02-22 |
2019-05-01 |
CureVac AG |
Combination of vaccination and inhibition of the pd-1 pathway
|
|
US9974845B2
(en)
|
2013-02-22 |
2018-05-22 |
Curevac Ag |
Combination of vaccination and inhibition of the PD-1 pathway
|
|
KR102164405B1
(ko)
|
2013-03-14 |
2020-10-12 |
더 존스 홉킨스 유니버시티 |
나노스케일 인공 항원 제시 세포
|
|
EP2983702A2
(en)
*
|
2013-04-07 |
2016-02-17 |
The Broad Institute, Inc. |
Compositions and methods for personalized neoplasia vaccines
|
|
WO2014180490A1
(en)
|
2013-05-10 |
2014-11-13 |
Biontech Ag |
Predicting immunogenicity of t cell epitopes
|
|
WO2015048744A2
(en)
|
2013-09-30 |
2015-04-02 |
Moderna Therapeutics, Inc. |
Polynucleotides encoding immune modulating polypeptides
|
|
WO2015077717A1
(en)
|
2013-11-25 |
2015-05-28 |
The Broad Institute Inc. |
Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
|
|
WO2015085147A1
(en)
|
2013-12-05 |
2015-06-11 |
The Broad Institute Inc. |
Polymorphic gene typing and somatic change detection using sequencing data
|
|
US20160310584A1
(en)
*
|
2013-12-06 |
2016-10-27 |
The Broad Institute Inc. |
Formulations for neoplasia vaccines
|
|
KR20230076867A
(ko)
*
|
2013-12-20 |
2023-05-31 |
더 브로드 인스티튜트, 인코퍼레이티드 |
신생항원 백신과의 병용 요법
|
|
EP3090066A4
(en)
*
|
2014-01-02 |
2017-08-30 |
Memorial Sloan Kettering Cancer Center |
Determinants of cancer response to immunotherapy
|
|
CA2935878C
(en)
|
2014-03-12 |
2023-05-02 |
Curevac Ag |
Combination of vaccination and ox40 agonists
|
|
EP3137100B1
(en)
|
2014-04-15 |
2023-12-20 |
University Of Virginia Patent Foundation |
Isolated t cell receptors and methods of use therefor
|
|
CN113791220A
(zh)
*
|
2014-09-10 |
2021-12-14 |
豪夫迈·罗氏有限公司 |
免疫原性突变体肽筛选平台
|
|
EP3191121B1
(en)
*
|
2014-09-10 |
2020-05-27 |
The University of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
US11338026B2
(en)
|
2014-09-10 |
2022-05-24 |
The University Of Connecticut |
Identification of immunologically protective neo-epitopes for the treatment of cancers
|
|
WO2016040900A1
(en)
*
|
2014-09-14 |
2016-03-17 |
Washington University |
Personalized cancer vaccines and methods therefor
|
|
CA3017170C
(en)
|
2014-09-17 |
2021-03-23 |
The Johns Hopkins University |
Reagents and methods for identifying, enriching, and/or expanding antigen-specific t cells
|
|
SI3193917T1
(sl)
*
|
2014-09-17 |
2022-02-28 |
Io Biotech Aps |
Sestavki cepiva, ki vsebujejo triptofan 2,3-dioksigenazo ali njene delce
|
|
WO2016045732A1
(en)
|
2014-09-25 |
2016-03-31 |
Biontech Rna Pharmaceuticals Gmbh |
Stable formulations of lipids and liposomes
|
|
JP6599450B2
(ja)
|
2014-10-02 |
2019-10-30 |
アメリカ合衆国 |
がん特異的突然変異に対し抗原特異性を有するｔ細胞を単離する方法
|
|
JP6991857B2
(ja)
*
|
2014-10-10 |
2022-01-13 |
イデラ ファーマシューティカルズ インコーポレイテッド |
Ｔｌｒ９アゴニストをチェックポイント阻害剤と共に用いるがんの治療
|
|
MA40737A
(fr)
*
|
2014-11-21 |
2017-07-04 |
Memorial Sloan Kettering Cancer Center |
Déterminants de la réponse d'un cancer à une immunothérapie par blocage de pd-1
|
|
US10975442B2
(en)
|
2014-12-19 |
2021-04-13 |
Massachusetts Institute Of Technology |
Molecular biomarkers for cancer immunotherapy
|
|
EP3234130B1
(en)
|
2014-12-19 |
2020-11-25 |
The Broad Institute, Inc. |
Methods for profiling the t-cell- receptor repertoire
|
|
WO2016128060A1
(en)
*
|
2015-02-12 |
2016-08-18 |
Biontech Ag |
Predicting t cell epitopes useful for vaccination
|
|
JP2018516847A
(ja)
|
2015-03-25 |
2018-06-28 |
ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン |
生体高分子薬を送達するための組成物及び方法
|
|
US20190099475A1
(en)
*
|
2015-04-08 |
2019-04-04 |
Nantomics, Llc |
Cancer neoepitopes
|
|
BR112017022845A2
(pt)
|
2015-04-23 |
2018-07-17 |
Nantomics, Llc |
neoepítopos de câncer
|
|
GB201507030D0
(en)
|
2015-04-24 |
2015-06-10 |
Immatics Biotechnologies Gmbh |
Immunotherapy against lung cancers, in particular NSCLC
|
|
CN117467603A
(zh)
*
|
2015-04-27 |
2024-01-30 |
癌症研究技术有限公司 |
治疗癌症的方法
|
|
WO2016179006A1
(en)
|
2015-05-01 |
2016-11-10 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of isolating t cells and t cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
|
|
EA201792501A1
(ru)
|
2015-05-13 |
2018-10-31 |
Эйдженус Инк. |
Вакцины для лечения и профилактики рака
|
|
IL294183B2
(en)
*
|
2015-05-20 |
2023-10-01 |
Dana Farber Cancer Inst Inc |
shared neoantigens
|
|
TW202241500A
(zh)
*
|
2015-06-09 |
2022-11-01 |
美商博德研究所有限公司 |
用於贅瘤疫苗之調配物及其製備方法
|
|
EP3323070B1
(en)
|
2015-07-14 |
2024-05-08 |
Personal Genome Diagnostics Inc. |
Neoantigen analysis
|
|
MA42543A
(fr)
|
2015-07-30 |
2018-06-06 |
Modernatx Inc |
Arn épitope peptidiques concatémériques
|
|
GB201516047D0
(en)
|
2015-09-10 |
2015-10-28 |
Cancer Rec Tech Ltd |
Method
|
|
EP3350600A4
(en)
*
|
2015-09-18 |
2019-04-17 |
Baylor College of Medicine |
DISTINCTION OF AN IMMUNOGENIC ANTIGEN OF A PATHOGEN AND CORRELATION WITH CLINICAL EFFECTIVENESS
|
|
WO2017059902A1
(en)
|
2015-10-07 |
2017-04-13 |
Biontech Rna Pharmaceuticals Gmbh |
3' utr sequences for stabilization of rna
|
|
EP3362929B1
(en)
|
2015-10-12 |
2020-08-12 |
Nantomics, LLC |
Viral neoepitopes and uses thereof
|
|
MX2018004544A
(es)
*
|
2015-10-12 |
2018-11-09 |
Nantomics Llc |
Composiciones y métodos para los neoepítopos de cáncer viral.
|
|
CN108700592B
(zh)
*
|
2015-10-12 |
2021-08-24 |
南托米克斯有限责任公司 |
新表位的迭代发现及其适应性免疫疗法和方法
|
|
CA3003251A1
(en)
*
|
2015-10-12 |
2017-04-20 |
Nantomics, Llc |
Systems, compositions, and methods for discovery of msi and neoepitopes that predict sensitivity to checkpoint inhibitors
|
|
AU2016341309A1
(en)
*
|
2015-10-22 |
2018-06-07 |
Modernatx, Inc. |
Cancer vaccines
|
|
EP3371594A1
(en)
|
2015-11-06 |
2018-09-12 |
Ventana Medical Systems, Inc. |
Representative diagnostics
|
|
TWI733719B
(zh)
*
|
2015-12-07 |
2021-07-21 |
美商河谷控股Ｉｐ有限責任公司 |
改善的組合物及用於新表位之病毒遞送的方法及其應用
|
|
ES2970865T3
(es)
*
|
2015-12-16 |
2024-05-31 |
Gritstone Bio Inc |
Identificación, fabricación y uso de neoantígenos
|
|
US11135221B2
(en)
*
|
2015-12-23 |
2021-10-05 |
Moonshot Pharma Llc |
Methods for inducing an immune response
|
|
IL260030B2
(en)
|
2016-01-08 |
2025-12-01 |
Nykode Therapeutics ASA |
Therapeutic anticancer neoepitope vaccine
|
|
US20170224796A1
(en)
|
2016-02-05 |
2017-08-10 |
Xeme Biopharma Inc. |
Therapeutic Cancer Vaccine Containing Tumor-Associated Neoantigens and Immunostimulants in a Delivery System
|
|
WO2017139694A1
(en)
*
|
2016-02-12 |
2017-08-17 |
Nantomics, Llc |
High-throughput identification of patient-specific neoepitopes as therapeutic targets for cancer immunotherapies
|
|
CN105720176A
(zh)
*
|
2016-02-19 |
2016-06-29 |
京东方科技集团股份有限公司 |
一种胶囊量子点和发光二极管、制备方法及显示装置
|
|
WO2017143092A1
(en)
|
2016-02-19 |
2017-08-24 |
Nant Holdings Ip, Llc |
Methods of immunogenic modulation
|
|
KR20180117227A
(ko)
*
|
2016-03-24 |
2018-10-26 |
난트셀, 인크. |
네오에피토프 제시를 위한 시퀀스들 및 시퀀스 배열들
|
|
CA3056212A1
(en)
*
|
2016-04-07 |
2017-10-12 |
Bostongene Corporation |
Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines
|
|
US20190062272A1
(en)
*
|
2016-04-13 |
2019-02-28 |
Capten Therapeutics Inc. |
Small molecules for immunogenic treatment of cancer
|
|
US12257352B2
(en)
|
2016-06-20 |
2025-03-25 |
The Regents Of The University Of Michigan |
Compositions and methods for delivery of biomacromolecule agents
|
|
US20190247435A1
(en)
*
|
2016-06-29 |
2019-08-15 |
The Johns Hopkins University |
Neoantigens as targets for immunotherapy
|
|
CN109789092A
(zh)
|
2016-07-13 |
2019-05-21 |
哈佛学院院长等 |
抗原呈递细胞模拟支架及其制备和使用方法
|
|
SG11201900132QA
(en)
*
|
2016-07-20 |
2019-02-27 |
Biontech Rna Pharmaceuticals Gmbh |
Selecting neoepitopes as disease-specific targets for therapy with enhanced efficacy
|
|
AU2017305396A1
(en)
*
|
2016-08-02 |
2019-02-21 |
Nant Holdings Ip, Llc |
Transfection of dendritic cells and methods therefor
|
|
US20190237158A1
(en)
*
|
2016-08-31 |
2019-08-01 |
Medgenome, Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
US10350280B2
(en)
|
2016-08-31 |
2019-07-16 |
Medgenome Inc. |
Methods to analyze genetic alterations in cancer to identify therapeutic peptide vaccines and kits therefore
|
|
MX2019002925A
(es)
|
2016-09-15 |
2019-09-05 |
Idera Pharmaceuticals Inc |
Modulacion inmune con agonistas de tlr9 para el tratamiento del cancer.
|
|
WO2018057447A1
(en)
*
|
2016-09-23 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Methods of preparing an isolated population of dendritic cells and methods of treating cancer using same
|
|
WO2018071796A2
(en)
*
|
2016-10-13 |
2018-04-19 |
The Johns Hopkins University |
Compositions and methods for identifying functional anti-tumor t cell responses
|
|
CN110520530A
(zh)
*
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
WO2018089637A1
(en)
|
2016-11-11 |
2018-05-17 |
Nantbio, Inc. |
Immunomodulatory compositions, processes for making the same, and methods for inhibiting cytokine storms
|
|
WO2018102613A2
(en)
|
2016-12-01 |
2018-06-07 |
Nantomics, Llc |
Tumor antigenicity processing and presentation
|
|
US11549149B2
(en)
|
2017-01-24 |
2023-01-10 |
The Broad Institute, Inc. |
Compositions and methods for detecting a mutant variant of a polynucleotide
|
|
BR112019015797A2
(pt)
*
|
2017-02-01 |
2020-03-17 |
Modernatx, Inc. |
Composições de mrna terapêuticas imunomoduladoras que codificam peptídeos de mutação de oncogene de ativação
|
|
US20190351040A1
(en)
*
|
2017-02-01 |
2019-11-21 |
Modernatx, Inc. |
Rna cancer vaccines
|
|
US10859566B2
(en)
|
2017-03-20 |
2020-12-08 |
Genocea Biosciences, Inc. |
Treatment methods
|
|
WO2018183544A1
(en)
*
|
2017-03-31 |
2018-10-04 |
Dana-Farber Cancer Institute, Inc. |
Method for identification of retained intron tumor neoantigens from patient transcriptome
|
|
CA3058807A1
(en)
|
2017-04-03 |
2018-10-11 |
Biontech Us Inc. |
Protein antigens and uses thereof
|
|
WO2018187515A1
(en)
|
2017-04-04 |
2018-10-11 |
Avidea Technologies, Inc. |
Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
|
|
CA3060569A1
(en)
*
|
2017-04-19 |
2018-10-25 |
Gritstone Oncology, Inc. |
Neoantigen identification, manufacture, and use
|
|
US11779637B2
(en)
|
2017-04-24 |
2023-10-10 |
Nantcell, Inc. |
Targeted neoepitope vectors and methods therefor
|
|
EP3634449A4
(en)
|
2017-05-08 |
2021-03-17 |
Gritstone Oncology, Inc. |
ALPHAVIRUS NEOANTIGEN VECTORS
|
|
US20200199660A1
(en)
|
2017-05-10 |
2020-06-25 |
The Broad Institute, Inc. |
Methods and compositions for determination of mutations in single replication events
|
|
EP3622092A4
(en)
|
2017-05-11 |
2021-06-23 |
The Broad Institute, Inc. |
METHODS AND COMPOSITIONS OF USE OF CD8 + TUMOR-INFILTRATING LYMPHOCYTE SUBTYPES AND GENE SIGNATURES THEREOF
|
|
JP2020522479A
(ja)
*
|
2017-06-02 |
2020-07-30 |
アリゾナ ボード オブ リージェンツ オン ビハーフ オブ アリゾナ ステート ユニバーシティ |
個別化された癌ワクチンを作製する方法
|
|
WO2018224166A1
(en)
|
2017-06-09 |
2018-12-13 |
Biontech Rna Pharmaceuticals Gmbh |
Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy
|
|
WO2018234506A2
(en)
*
|
2017-06-21 |
2018-12-27 |
Transgene Sa |
PERSONALIZED VACCINE
|
|
US12049643B2
(en)
|
2017-07-14 |
2024-07-30 |
The Broad Institute, Inc. |
Methods and compositions for modulating cytotoxic lymphocyte activity
|
|
TWI832820B
(zh)
|
2017-07-21 |
2024-02-21 |
美商伯克利之光生命科技公司 |
抗原呈現合成表面、共價功能化表面、經活化之t細胞及其用途
|
|
WO2019023269A1
(en)
|
2017-07-25 |
2019-01-31 |
California Institute Of Technology |
DISCOVERING TROGOCYTOSE MEDIATION EPITOPES
|
|
WO2019036043A2
(en)
*
|
2017-08-16 |
2019-02-21 |
Medgenome Inc. |
METHOD FOR GENERATING A COCKTAIL OF PERSONALIZED ANTICANCER VACCINES FROM TUMOR DERIVED GENETIC MODIFICATIONS FOR THE TREATMENT OF CANCER
|
|
US12025615B2
(en)
|
2017-09-15 |
2024-07-02 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods of classifying response to immunotherapy for cancer
|
|
CA3076918A1
(en)
*
|
2017-10-02 |
2019-04-11 |
Curematch, Inc. |
Method of prediction of tumor-derived neo-peptide antigenicity and/or immunogenicity using mutational signature patterns
|
|
RU2020115161A
(ru)
*
|
2017-10-06 |
2021-11-08 |
Дзе Уистар Инститьют Оф Энэтоми Энд Байолоджи |
Днк моноклональных антител против ctla-4 для лечения и профилактики рака
|
|
EP4576103A3
(en)
|
2017-10-10 |
2025-08-27 |
Gritstone bio, Inc. |
Neoantigen identification using hotspots
|
|
EP3707245A1
(en)
*
|
2017-11-06 |
2020-09-16 |
Ludwig Institute for Cancer Research Ltd |
Method for expansion of lymphocytes
|
|
WO2019094396A1
(en)
*
|
2017-11-07 |
2019-05-16 |
Nektar Therapeutics |
Immunotherapeutic combination for treating cancer
|
|
SG11202004116QA
(en)
|
2017-11-08 |
2020-06-29 |
Biontech Us Inc |
T cell manufacturing compositions and methods
|
|
CN111630602A
(zh)
|
2017-11-22 |
2020-09-04 |
磨石肿瘤生物技术公司 |
减少新抗原的接合表位呈递
|
|
CN109682978B
(zh)
*
|
2017-11-30 |
2020-07-03 |
四川康德赛医疗科技有限公司 |
一种肿瘤突变肽mhc亲和力预测方法及其应用
|
|
TW201930340A
(zh)
|
2017-12-18 |
2019-08-01 |
美商尼恩醫療公司 |
新抗原及其用途
|
|
MX2020007077A
(es)
|
2018-01-04 |
2020-10-28 |
Iconic Therapeutics Inc |
Anticuerpos anti-factor tisular, conjugados anticuerpo-farmaco y metodos relacionados.
|
|
EP3743102A1
(en)
|
2018-01-26 |
2020-12-02 |
Nantcell, Inc. |
Compositions and methods for combination cancer vaccine and immunologic adjuvant therapy
|
|
WO2019147921A1
(en)
|
2018-01-26 |
2019-08-01 |
Nantcell, Inc. |
Rapid verification of virus particle production for a personalized vaccine
|
|
CN108491689B
(zh)
*
|
2018-02-01 |
2019-07-09 |
杭州纽安津生物科技有限公司 |
基于转录组的肿瘤新抗原鉴定方法
|
|
EP3759131A4
(en)
*
|
2018-02-27 |
2021-12-01 |
Gritstone bio, Inc. |
NEOANTIGEN IDENTIFICATION WITH PAN ALLELE MODELS
|
|
MA52363A
(fr)
|
2018-04-26 |
2021-03-03 |
Agenus Inc |
Compositions peptidiques de liaison à une protéine de choc thermique (hsp) et leurs méthodes d'utilisation
|
|
AU2019275072A1
(en)
|
2018-05-23 |
2021-01-21 |
Seattle Project Corp. |
Shared antigens
|
|
WO2019227106A1
(en)
|
2018-05-25 |
2019-11-28 |
The Wistar Institute |
Tumor-specific neoantigens and methods of using the same
|
|
WO2019241315A1
(en)
|
2018-06-12 |
2019-12-19 |
Obsidian Therapeutics, Inc. |
Pde5 derived regulatory constructs and methods of use in immunotherapy
|
|
MX2020014243A
(es)
|
2018-06-19 |
2021-05-12 |
Biontech Us Inc |
Neoantigenos y usos de los mismos.
|
|
IL280113B2
(en)
|
2018-07-26 |
2025-11-01 |
Curevac Netherlands B V |
Cancer vaccines for uterine cancer
|
|
WO2020022900A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for kidney cancer
|
|
WO2020022903A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
ARID1A, CDKN2A, KMT2B, KMT2D, TP53 and PTEN VACCINES FOR CANCER
|
|
US20220349010A1
(en)
|
2018-07-26 |
2022-11-03 |
Frame Pharmaceuticals B.V. |
Method of preparing subject-specific immunogenic compositions based on a neo open-reading-frame peptide database
|
|
CA3106564A1
(en)
|
2018-07-26 |
2020-01-30 |
Frame Pharmaceuticals B.V. |
Cancer vaccines for breast cancer
|
|
IL321692A
(en)
|
2018-07-26 |
2025-08-01 |
Curevac Netherlands B V |
Cancer vaccines for colorectal cancer
|
|
CN109021062B
(zh)
*
|
2018-08-06 |
2021-08-20 |
倍而达药业（苏州）有限公司 |
一种肿瘤新抗原的筛选方法
|
|
CN121354685A
(zh)
|
2018-08-31 |
2026-01-16 |
夸登特健康公司 |
无细胞dna中的微卫星不稳定性检测
|
|
GB201815041D0
(en)
|
2018-09-14 |
2018-10-31 |
Scancell Ltd |
Epitopes
|
|
TW202028224A
(zh)
|
2018-09-17 |
2020-08-01 |
德商英麥提克生物技術股份有限公司 |
B*44限制肽在抗癌免疫治療的用途和相關方法
|
|
US11993766B2
(en)
|
2018-09-21 |
2024-05-28 |
Bruker Cellular Analysis, Inc. |
Functionalized well plate, methods of preparation and use thereof
|
|
MX2021003654A
(es)
|
2018-09-27 |
2021-05-28 |
Nykode Therapeutics AS |
Metodo para seleccionar neoepitopes.
|
|
KR20210078526A
(ko)
|
2018-10-18 |
2021-06-28 |
버클리 라잇츠, 인크. |
원 항원 제시 합성 표면, 활성화된 t 세포, 및 이들의 용도
|
|
SG11202104611YA
(en)
|
2018-11-08 |
2021-06-29 |
Neximmune Inc |
T cell compositions with improved phenotypic properties
|
|
US20220062394A1
(en)
|
2018-12-17 |
2022-03-03 |
The Broad Institute, Inc. |
Methods for identifying neoantigens
|
|
CN109706065A
(zh)
*
|
2018-12-29 |
2019-05-03 |
深圳裕策生物科技有限公司 |
肿瘤新生抗原负荷检测装置及存储介质
|
|
MX2021010089A
(es)
|
2019-02-20 |
2021-12-10 |
Rubius Therapeutics Inc |
Células eritroides diseñadas que incluyen polipéptidos que presentan antígeno cargable y métodos de uso.
|
|
CN111621564B
(zh)
*
|
2019-02-28 |
2022-03-25 |
武汉大学 |
一种鉴定有效肿瘤新抗原的方法
|
|
US12427195B1
(en)
*
|
2019-03-11 |
2025-09-30 |
La Jolla Institute For Immunology |
Methods of neoantigen identification
|
|
WO2020185010A1
(ko)
*
|
2019-03-12 |
2020-09-17 |
(주)신테카바이오 |
인공지능모델기반 분자동역학 빅데이터를 활용한 신생항원 면역치료정보 제공 시스템 및 방법
|
|
EP3963335B1
(en)
*
|
2019-05-03 |
2024-08-21 |
Epivax Therapeutics, Inc. |
Neoantigens in cancer
|
|
WO2020227255A1
(en)
*
|
2019-05-06 |
2020-11-12 |
The Regents Of The University Of Michigan |
Targeted therapy
|
|
CN112011833B
(zh)
*
|
2019-05-30 |
2024-04-26 |
上海桀蒙生物技术有限公司 |
筛选和分离肿瘤新生抗原的方法
|
|
MX2021014525A
(es)
|
2019-05-30 |
2022-03-17 |
Gritstone Bio Inc |
Adenovirus modificados.
|
|
CN110322925B
(zh)
*
|
2019-07-18 |
2021-09-03 |
杭州纽安津生物科技有限公司 |
一种预测融合基因产生新生抗原的方法
|
|
CN110706747B
(zh)
*
|
2019-09-17 |
2021-09-07 |
北京橡鑫生物科技有限公司 |
检测肿瘤新生抗原多肽的方法和装置
|
|
WO2021067550A1
(en)
|
2019-10-02 |
2021-04-08 |
Arizona Board Of Regents On Behalf Of Arizona State University |
Methods and compositions for identifying neoantigens for use in treating and preventing cancer
|
|
US11920202B2
(en)
|
2020-04-09 |
2024-03-05 |
University Of Connecticut |
Unbiased identification of tumor rejection mediating neoepitopes
|
|
US20230212243A1
(en)
*
|
2020-05-12 |
2023-07-06 |
Institut Curie |
Neoantigenic Epitopes Associated with SF3B1 Mutations
|
|
JP7153287B2
(ja)
*
|
2020-05-12 |
2022-10-14 |
住友ファーマ株式会社 |
癌を処置するための医薬組成物
|
|
WO2021252904A1
(en)
|
2020-06-11 |
2021-12-16 |
Massachusetts Institute Of Technology |
Ribonucleoprotein approach to boost the sting signaling for cancer immunotherapy
|
|
CN116438308A
(zh)
|
2020-08-06 |
2023-07-14 |
磨石生物公司 |
多表位疫苗盒
|
|
MX2023001815A
(es)
|
2020-08-13 |
2023-04-11 |
Biontech Us Inc |
Metodos y composiciones de fabricacion de celulas t.
|
|
GB2613718A
(en)
*
|
2020-08-31 |
2023-06-14 |
World Biotech Regenerative Medical Group Ltd |
Personalized immunogenic compositions and methods for producing and using same
|
|
KR102552632B1
(ko)
*
|
2020-11-06 |
2023-07-06 |
사회복지법인 삼성생명공익재단 |
중추신경계 림프종을 진단하기 위한 마커, 이를 포함하는 중추신경계 림프종 진단 키트 및 중추신경계 림프종을 진단하는 방법
|
|
AU2022245391A1
(en)
*
|
2021-03-26 |
2023-10-12 |
The Translational Genomics Research Institute |
Methods and compounds for neoantigen vaccines
|
|
JP2024517793A
(ja)
|
2021-04-30 |
2024-04-23 |
ティゲン・ファーマ・ソシエテ・アノニム |
単一容器リンパ球拡大
|
|
US20230173046A1
(en)
*
|
2021-05-27 |
2023-06-08 |
Amazon Technologies, Inc. |
Multicomponent chemical composition of a peptide-based neoantigen vaccine
|
|
WO2023025404A1
(en)
|
2021-08-24 |
2023-03-02 |
BioNTech SE |
In vitro transcription technologies
|
|
CN115772564B
(zh)
*
|
2021-09-08 |
2023-08-18 |
广州市基准医疗有限责任公司 |
用于辅助检测肺癌体细胞atm基因融合突变的甲基化生物标记物及其应用
|
|
EP4419716A1
(en)
|
2021-10-21 |
2024-08-28 |
CureVac Netherlands B.V. |
Cancer neoantigens
|
|
CN116287158A
(zh)
*
|
2021-12-08 |
2023-06-23 |
初源海生物科技(深圳)有限公司 |
一种新抗原鉴定和疗效预测方法
|
|
CN119072330A
(zh)
|
2022-03-14 |
2024-12-03 |
世代生物公司 |
异源初免加强疫苗组合物和使用方法
|
|
WO2024077256A1
(en)
|
2022-10-07 |
2024-04-11 |
The General Hospital Corporation |
Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
|
|
WO2024083345A1
(en)
|
2022-10-21 |
2024-04-25 |
BioNTech SE |
Methods and uses associated with liquid compositions
|
|
WO2024097864A1
(en)
|
2022-11-02 |
2024-05-10 |
Tigen Pharma Sa |
Expansion of lymphocytes
|
|
US12531162B1
(en)
*
|
2023-05-31 |
2026-01-20 |
Northeastern University |
Multi-dimensional phenotypic space for genotype to phenotype mapping and intelligent design of cancer drug therapies using a deep learning net
|
|
EP4474016A1
(en)
|
2023-06-07 |
2024-12-11 |
Julius-Maximilians-Universität Würzburg |
Strategies to target extracellularly accessible ras protein
|
|
WO2024261339A1
(en)
|
2023-06-23 |
2024-12-26 |
Tigen Pharma Sa |
Lymphocyte-stimulatory matrix (lsm) and uses thereof for expansion of lymphocyte populations
|
|
US12562256B2
(en)
*
|
2023-11-07 |
2026-02-24 |
New York University |
Systems, methods and computer-accessible medium for identifying target pairs for CAR-T therapy
|
|
WO2025202937A1
(en)
|
2024-03-26 |
2025-10-02 |
BioNTech SE |
Cancer vaccines
|